The pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity (often an early indication one is on the way), nausea and a throbbing pain behind the eyes and in the temples.
Heptares Therapeutics is a UK biotech which looks to treat such a condition, with a broad neurological drug portfolio to include other indications like Alzheimer’s, Schizophrenia and ADHD. Founded by Fiona Marshall (one of our Top 10 UK Women in Biotech), she now serves as a CSO to Japanese Big boss Sosei, which wholly acquired Heptares earlier this year in a €373M deal. Other partners include Takeda, AstraZeneca, Cubist Pharma (US), MorphoSys and MedImmune.